Company Performance - Organon (OGN) closed at $9.70, reflecting a -3.39% change from the previous day's closing price, underperforming the S&P 500's daily loss of 0.37% [1] - The stock has decreased by 1.08% over the past month, lagging behind the Medical sector's loss of 0.88% and the S&P 500's gain of 2.68% [1] Earnings Forecast - Organon is expected to release earnings on August 5, 2025, with a predicted EPS of $0.94, indicating a 16.07% decline compared to the same quarter last year [2] - Revenue is anticipated to be $1.55 billion, reflecting a 3.35% decrease from the same quarter last year [2] Full Year Estimates - For the full year, analysts project earnings of $3.83 per share and revenue of $6.24 billion, marking changes of -6.81% and -2.48% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Organon indicate short-term business trends, with positive revisions suggesting analysts' confidence in the company's performance [4] Zacks Rank and Valuation - Organon currently holds a Zacks Rank of 2 (Buy), with a consensus EPS projection that has increased by 0.55% in the past 30 days [6] - The company is trading at a Forward P/E ratio of 2.62, significantly lower than the industry average of 15.82, indicating a potential discount [7] Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 94, placing it in the top 39% of over 250 industries [8]

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/organon-co-lawsuit-submission-for ...

NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Organon & Co.("Organon" or the "Company") (NYSE: OGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. Danielle Peyton Pomerantz LLP The class action concerns whether Organon and c ...

Core Viewpoint - A class action securities lawsuit has been filed against Organon & Co. due to alleged securities fraud that negatively impacted investors between October 31, 2024, and April 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Organon's management made overly positive statements while concealing material adverse facts about the company's capital allocation priorities, particularly regarding a significant debt reduction strategy following the acquisition of Dermavant [2]. - As a result of these actions, Organon reduced its regular quarterly dividend by 70%, leading to a dramatic decline in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a drop of over 27% in just one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 22, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly providing misleading statements to investors while concealing material adverse facts regarding the company's capital allocation priorities, particularly concerning its dividend strategy [2][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased Organon securities between November 3, 2022, and April 30, 2025, with a deadline of July 22, 2025, for investors to apply as lead plaintiffs [2]. - The complaint alleges that the defendants made overwhelmingly positive statements while hiding the true state of Organon's priorities, especially regarding its debt reduction strategy after acquiring Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. Group 2: Stock Price Impact - Following the announcement of the lawsuit and the revelations regarding the dividend cut, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to misleading statements and a significant reduction in quarterly dividends, which led to a sharp decline in stock price [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from October 31, 2024, to April 30, 2025 [3]. - Allegations include that Organon provided overly positive statements while concealing material adverse facts about its capital allocation priorities, particularly regarding a debt reduction strategy following the acquisition of Dermavant [3]. Impact on Stock Price - Following the announcement of the dividend reduction, Organon's stock price dropped from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 22, 2025, to potentially become lead plaintiffs and receive updates on the case [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to false or misleading statements by companies [5].

Core Viewpoint - Investors in the Medical Services sector should consider Organon (OGN) and Medpace (MEDP) as potential undervalued stocks, with OGN appearing to be the superior option based on valuation metrics and earnings estimate revisions [1][7]. Valuation Metrics - OGN has a forward P/E ratio of 2.47, significantly lower than MEDP's forward P/E of 24.59, indicating that OGN may be undervalued relative to MEDP [5]. - The PEG ratio for OGN is 0.94, while MEDP's PEG ratio is 5.64, suggesting that OGN's expected earnings growth is more favorable compared to its price [5]. - OGN's P/B ratio is 4.54, compared to MEDP's P/B of 15.1, further highlighting OGN's more attractive valuation [6]. Analyst Outlook - OGN currently holds a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while MEDP has a Zacks Rank of 3 (Hold), suggesting a less favorable outlook [3]. - The stronger estimate revision activity for OGN, combined with its attractive valuation metrics, positions it as a more appealing choice for value investors [7].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for alleged misrepresentations regarding its capital allocation priorities and risks associated with its product Nexplanon during the class period from November 3, 2022, to April 30, 2025 [1][3][4] Company Overview - Organon & Co. is a healthcare company based in Jersey City, NJ, focusing on women's health [2] - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2] Lawsuit Details - The lawsuit claims that despite increasing debt from the Dermavant acquisition, Organon assured investors it would maintain its dividend as its "1 capital allocation priority" [3] - It is alleged that after the acquisition, Organon shifted its capital allocation focus towards reducing debt rather than maintaining dividends [3] - The lawsuit also states that Organon failed to disclose the heightened risk of loss of exclusivity and price erosion related to its product Nexplanon [4]

SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Organon & Co. (NYSE: OGN) publicly traded securities between November 3, 2022 and April 30, 2025, inclusive (the "Class Period"). Captioned Lerner v. Organon & Co., No. 25-cv-12983 (D.N.J.), the Organon class action lawsuit charges Organon as well as certain of Organon's top executives with violations of the Securities Exchange Ac ...

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about dividend policies following a significant acquisition [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, specifically titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].